Treatments cut risk of new brain metastases

The use of bevacizumab and immune checkpoint inhibitors can each reduce the risk of new brain metastases by about 30%, according to findings from new meta-analyses presented at SNO 2020.

Researchers from Penn State Health and Penn State Hershey Medical Center, in Hershey, Pennsylvania, and from the University of Texas Southwestern, in Dallas, USA, performed a systematic literature review for data published between January 2000 and June 2020, to drive two analyses.